Bullish on AbCellera Biologics citing multiple 2026 upside triggers and compelling risk/reward.
ABCL — LONG The author argues AbCellera is a buy at current levels because 2026 has multiple upside triggers: new AI-driven discovery partnerships, milestone and royalty revenue inflection, and clinical progress from partnered programs. Improving biotech sentiment further supports the risk/reward, which the author sees as increasingly compelling.
Risk/reward increasingly compelling at these levels.
This Reddit post, published January 06, 2026, features u/HedgeBullish discussing ABCL. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/HedgeBullish · Tickers: ABCL